Search Results for "Iclusig"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Iclusig. Results 1 to 1 of 1 total matches.
See also: ponatinib
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
OTHER SECOND-LINE DRUGS — The oral kinase
inhibitor ponatinib (Iclusig) has been available for
years ...
Asciminib (Scemblix – Novartis), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+ CML) in chronic
phase (CP) previously treated with ≥2 tyrosine kinase
inhibitors and for adults with Ph+ CML in CP with a
T315I mutation.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-8 doi:10.58347/tml.2023.1678g | Show Introduction Hide Introduction